Navigation Links
CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
Date:6/16/2009

euronal damage is also implicated in the peripheral neuropathies associated with diabetes, kidney disease, cancer chemotherapy and other conditions. In preclinical studies, CXB909 enhanced the action of NGF in vitro, amplifying its activity almost seven-fold. CXB909 was neuroprotective in a variety of cellular assays and in animal models of neuropathies and neurodegenerative diseases, including chemotherapy-induced neuropathy, for which there is currently no approved treatment.

"The addition of CXB909 to our development pipeline is another example of the growing success of our strategy to in-license novel CNS agents with validated mechanisms for the treatment of underserved CNS disorders," said Barry Brand, Chief Executive Officer of CeNeRx. "Our rapidly aging population is at risk for devastating neuropathic and neurodegenerative diseases that lack effective therapies. We intend to move quickly to test CXB909 in relevant conditions, beginning with chemotherapy-induced peripheral neuropathy, a disabling and dose-limiting side effect of cancer treatment with a relatively straightforward pathway to clinical development and regulatory review."

CXB909 was licensed from Krenitsky Pharmaceuticals Inc., which also licensed the RIMA series of selective and reversible monoamine oxidase inhibitor (MAOI) compounds to CeNeRx. The lead compound in that program, TriRima(TM), is currently in a Phase II trial for the treatment of major depressive disorder. Further details of the new licensing agreement were not disclosed.

About CeNeRx BioPharma

CeNeRx is a privately held clinical stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system. CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, is in Phase II development for the treatment of major depressive disorder. RIMAs may have efficacy advant
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
2. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
3. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
4. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
5. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
7. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
11. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ... the fourth quarter of 2013 on Monday, February 3, 2014. ... after the close of trading. (Logo: ... to discuss the operating highlights and financial results for the ...
(Date:1/14/2014)... /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - a ... to place and insert the screw accurately - offers ... ligament) repair or reconstruction as it holds the bones ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw ...
(Date:1/14/2014)... VALHALLA, N.Y. , Jan. 14, 2014   Oligomerix, Inc. ... disease modifying therapeutics for Alzheimer,s disease (AD) and related ... headquarters to Valhalla, NY as ... additional laboratory space at New York Medical College. ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... a privately held personalized medicine company focused on cancer, ... C (GCC) Lymph Nodes (LN) Classification as a Prognostic ... Pooled Analysis" at the 2012 American Society of Clinical ... 21, 2012.  The data from the paper demonstrate the ...
... 23, 2012 InspireMD, Inc. (OTC BB: NSPR) (the ... the development and commercialization of its proprietary stent platform ... today announced its business objectives for 2012 and reviewed ... the Company,s proprietary MicroNet™ platform technology. ...
Cached Medicine Technology:Signal Genetics Announces Publication of Meta-Analysis of its Colon Cancer Test-Previstageā„¢ GCC Confirming Prognostic Capabilities in Patients with Colon Cancer 2InspireMD Provides Corporate Update, Plans for 2012 2InspireMD Provides Corporate Update, Plans for 2012 3InspireMD Provides Corporate Update, Plans for 2012 4InspireMD Provides Corporate Update, Plans for 2012 5InspireMD Provides Corporate Update, Plans for 2012 6
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... 2014 EcoHealth Alliance, a nonprofit organization that focuses ... comprehensive review today examining the current state of knowledge ... calls for improved global surveillance strategies to combat the ... of Ebola in West Africa that has claimed the ... and Liberia. According to the World Health Organization ...
(Date:4/17/2014)... research team led by Cesar A. Arias, M.D., Ph.D., ... Houston (UTHealth) has identified a new superbug that caused ... appeared in the April 17 issue of The ... superbug is part of a class of highly-resistant bacteria ... which is a major cause of hospital and community-associated ...
(Date:4/17/2014)... Meaningful long-term survival is possible for selected patients ... treated with cytoreductive surgery with Hyperthermic IntraPeritoneal Chemotherapy, ... physicians at Wake Forest Baptist Medical Center. , ... experience with cytoreductive surgery and HIPEC, said lead ... 20 years, worth of patient data shows that ...
(Date:4/17/2014)... A new study has found that India,s shocking rates ... debt-ridden farmers who are clinging to tiny smallholdings ... ,cash crops, such as cotton and coffee, that are ... supports a range of previous case studies that point ... sector following the ,liberalisation, of the nation,s economy during ...
Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3
... may extend life for those with tumors in bile duct, ... a second chemotherapy drug to the treatment regimen of people ... to new research. , This type of cancer -- which ... notoriously difficult to treat and often fatal. , "These ...
... ... fat deposits and reshapes the body. Clinically proven, the maximus system powered by TriLipo, ... inch-loss, cellulite reduction and lax skin tightening. , ... Tel Aviv, Israel (PRWEB) April 7, 2010 - ...
... Researchers from Boston University School of Medicine (BUSM) ... have discovered a new approach for identifying smokers at ... which appear in the April 7th issue of ... use a genomic approach to prevent lung cancer in ...
... Ford Hospital have found that infection with the hepatitis ... Using administrative data from more than 67,000 Henry ... period 1997-2008, 0.6% (17/3057) patients with hepatitis C infection ... the disease developed kidney cancer. After controlling ...
... American guts don,t, study finds, , WEDNESDAY, April 7 ... human intestinal tract that help everything from digesting food ... culture because of variations in diet, researchers now report. ... microbiology by researchers in France, who identified genes in ...
... Cancer cells grow so fast that they can outstrip their ... produce energy in a way that needs less oxygen but ... Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove ... that sugar supply, causing the cells to self destruct. ...
Cached Medicine News:Health News:Progress Made Against Tough-to-Treat Biliary Tract Cancers 2Health News:Progress Made Against Tough-to-Treat Biliary Tract Cancers 3Health News:Pollogen Launches the Maximus, Advanced Solution for Fat Reduction and Body Shaping based on Innovative TriLipo Technology 2Health News:Pollogen Launches the Maximus, Advanced Solution for Fat Reduction and Body Shaping based on Innovative TriLipo Technology 3Health News:Researchers discover new approach for identifying smokers at highest risk for developing lung cancer 2Health News:Henry Ford Hospital atudy: Hepatitis C infection doubles risk for kidney cancer 2Health News:You Are What Microbes You Eat 2Health News:You Are What Microbes You Eat 3Health News:New agent chokes off energy supply, kills cancer cells 2
... as BMP-7, is a member of a class ... Proteins. OP-1 Implant is known to induce new ... systems. The FDA approved OP-1 Implant under the ... Implant is now available across the country and ...
Cloward Dowel CL18 Used for Anterior Cervical Fusion and are preserved by Freeze-dried method....
... are dense corticocancellous allografts comprised ... providing structural integrity while allowing ... These allografts are available in ... allografts are processed from donor ...
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
Medicine Products: